title: [Anti-angiogenic drugs probable complement in cancer therapy].
abstract: This review outlines the current status of anti-angiogenic treatment, with emphasis on clinical trials. In pathological growth, vessels become hyperstimulated and dysfunctional, due to overexpression of angiogenic growth factors, such as vascular endothelial growth factor (VEGF). Thus, various anti-angiogenic substances have been developed that neutralize VEGF; others aim to reduce the capacity of the cells to respond to this factor. In addition, substances that are inhibitors of matrix metalloproteinases or agents that induce programmed cell death (apoptosis) of endothelial cells are being tested. Another class of angiogenesis inhibitors includes those that already are in clinical use but on other indications. The National Cancer Institute (NCI) in the USA provides information on on-going clinical trials, which are being conducted on patients suffering from different solid tumor diseases, such as cancer of the colon, lung, prostate and breast. For treatment regimens with anti-angiogenic substances it is important to consider the appropriate dosing and dose interval. The clinical trials have in many instances only recently been initiated and it is premature to predict the outcome, especially as patients in the trials suffer from seriously progressive disease that has previously been treated and found to be therapy-resistant. In many cases combination therapy with an anti-angiogenic substance together with radiation, chemotherapy or other types of conventional tumor treatment, appears promising.
authors.affiliation: Barnkirurgiska kliniken, Akademiska sjukhuset, Uppsala.
authors.forename: Rolf
authors.initials: R
authors.lastname: Christofferson
authors.forename: Lena
authors.initials: L
authors.lastname: Claesson-Welsh
authors.forename: Carin
authors.initials: C
authors.lastname: Muhr
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016228:Endothelial Growth Factors / Q000009:adverse effects / Q000502:physiology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D005346:Fibroblast Growth Factors / Q000009:adverse effects / Q000502:physiology; D006801:Humans; D008666:Metalloendopeptidases / Q000009:adverse effects / Q000502:physiology; D008954:Models, Biological; D009369:Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000517:prevention & control; D018919:Neovascularization, Physiologic / Q000502:physiology; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors / Q000502:physiology; D014055:Tomography, Emission-Computed
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016228:Endothelial Growth Factors; D017978:Receptors, Growth Factor; D005346:Fibroblast Growth Factors; D008666:Metalloendopeptidases